PE20151751A1 - Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble - Google Patents

Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble

Info

Publication number
PE20151751A1
PE20151751A1 PE2015001600A PE2015001600A PE20151751A1 PE 20151751 A1 PE20151751 A1 PE 20151751A1 PE 2015001600 A PE2015001600 A PE 2015001600A PE 2015001600 A PE2015001600 A PE 2015001600A PE 20151751 A1 PE20151751 A1 PE 20151751A1
Authority
PE
Peru
Prior art keywords
methods
iron deficiency
ferric pyrophosphate
treatment
soluble ferric
Prior art date
Application number
PE2015001600A
Other languages
English (en)
Inventor
Ajay Gupta
Original Assignee
Charak Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50097899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151751(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Charak Llc filed Critical Charak Llc
Publication of PE20151751A1 publication Critical patent/PE20151751A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)

Abstract

La invencion proporciona metodos de tratamiento de la deficiencia de hierro y metodos para reducir o eliminar la dosis de agente estimulante de la eritropoyesis para aumentar o mantener los niveles de hemoglobina en el rango objetivo en un sujeto que sufre de anemia, que comprende administrar pirofosfato ferrico soluble en una cantidad eficaz para mantener o aumentar los niveles de hemoglobina en el sujeto
PE2015001600A 2013-02-01 2014-02-01 Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble PE20151751A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361759531P 2013-02-01 2013-02-01

Publications (1)

Publication Number Publication Date
PE20151751A1 true PE20151751A1 (es) 2015-12-03

Family

ID=50097899

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001600A PE20151751A1 (es) 2013-02-01 2014-02-01 Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble

Country Status (20)

Country Link
US (3) US20150366907A1 (es)
EP (2) EP2950806B1 (es)
JP (3) JP2016507527A (es)
KR (1) KR102236714B1 (es)
CN (2) CN107007624A (es)
AU (3) AU2014212127A1 (es)
BR (1) BR112015018549A8 (es)
CA (1) CA2900043A1 (es)
CL (1) CL2015002171A1 (es)
EA (1) EA032407B1 (es)
HK (1) HK1215185A1 (es)
IL (1) IL240257A0 (es)
MX (1) MX370139B (es)
NI (1) NI201500100A (es)
PE (1) PE20151751A1 (es)
PH (1) PH12015501708A1 (es)
SG (1) SG11201506022VA (es)
TW (1) TW201517913A (es)
WO (1) WO2014121155A1 (es)
ZA (1) ZA201506364B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9980894B2 (en) 2012-06-15 2018-05-29 Symrise Ag Cosmetic compositions comprising hyaluronan biosynthesis promoting agents
KR20160091918A (ko) * 2013-11-05 2016-08-03 락웰 메디컬, 인코포레이티드 저반응성 환자에서 에리스로포이에틴 자극제의 용량을 감소시키는 방법
US11517555B2 (en) * 2015-09-04 2022-12-06 Rockwell Medical, Inc. Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
CN106581053A (zh) * 2015-10-20 2017-04-26 华仁药业股份有限公司 一种具有补铁功能的腹膜透析液
EP3842808A4 (en) * 2018-08-24 2022-05-18 National University Corporation Yokohama National University ADMINISTRATION MANAGEMENT APPARATUS, ADMINISTRATION MANAGEMENT METHOD AND PROGRAM
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
WO2021163209A1 (en) * 2020-02-11 2021-08-19 Quest Diagnostics Investments Llc System for determining an underlying cause of anemia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9713653B1 (pt) 1996-12-31 2013-05-21 composiÇço farmacÊutica, mÉtodo para preparar uma composiÇço farmacÊutica, e, uso de pirofosfato fÉrrico.
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
US6779648B2 (en) * 2000-07-13 2004-08-24 Psi Sales, Inc. 360 Degree rotatable lifter arm for log singulator
JP2005068055A (ja) * 2003-08-22 2005-03-17 Fujiyakuhin Co Ltd 無機元素含有水性コロイド分散液
US7857977B2 (en) * 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
ES2634142T3 (es) * 2005-12-23 2017-09-26 Ajay Gupta Composición de nutrición parenteral que contiene hierro
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
CA2819234A1 (en) * 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration

Also Published As

Publication number Publication date
CA2900043A1 (en) 2014-08-07
AU2018278891A1 (en) 2019-01-03
CL2015002171A1 (es) 2016-02-05
EA032407B1 (ru) 2019-05-31
JP2019151669A (ja) 2019-09-12
US20180280432A1 (en) 2018-10-04
CN104936609B (zh) 2017-04-12
KR20160004257A (ko) 2016-01-12
JP2021169525A (ja) 2021-10-28
CN107007624A (zh) 2017-08-04
SG11201506022VA (en) 2015-08-28
CN104936609A (zh) 2015-09-23
NZ710691A (en) 2020-09-25
JP2016507527A (ja) 2016-03-10
IL240257A0 (en) 2015-09-24
HK1215185A1 (zh) 2016-08-19
WO2014121155A1 (en) 2014-08-07
MX370139B (es) 2019-12-03
BR112015018549A2 (pt) 2017-07-18
ZA201506364B (en) 2022-07-27
KR102236714B1 (ko) 2021-04-06
PH12015501708A1 (en) 2015-10-12
EP2950806A1 (en) 2015-12-09
TW201517913A (zh) 2015-05-16
NI201500100A (es) 2019-05-07
AU2018278891B2 (en) 2020-09-10
BR112015018549A8 (pt) 2018-01-30
AU2014212127A1 (en) 2015-08-20
US20150366907A1 (en) 2015-12-24
EP2950806B1 (en) 2020-07-15
EP3789034A1 (en) 2021-03-10
MX2015009968A (es) 2016-03-11
AU2020286223A1 (en) 2021-01-07
EA201591424A1 (ru) 2015-12-30
US20200276232A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
PE20151751A1 (es) Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble
CO2019008487A2 (es) Compuesto de quinazolina
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201690980A1 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
CL2015000699A1 (es) Métodos para tratamiento de cáncer.
BR112017011536A2 (pt) terapias de combinação
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2022014277A (es) Metodos para una mejor administracion de agentes activos a tumores.
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
WO2015168102A3 (en) Prolonged protein stabilization by resveratrol
BR112015028334A2 (pt) agente e método para o tratamento de herpes
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.